OSCR Stock Analysis: Oscar Health | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 9.136m USD | 12M Return: 60.5% | US6877931096 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 167M
Qual. Beats: 2
Rev. Trend: 99.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Oscar Health, Inc. (NYSE: OSCR) is a U.S.-based healthcare technology company headquartered in New York, founded in 2012 and formerly known as Mulberry Health Inc. The company sells health insurance plans to individuals, families, employees, and small groups, and is a notable participant in the ACA individual marketplace. It also operates the +Oscar platform, a B2B technology offering that enables other healthcare players to build and manage insurance products, alongside the Campaign Builder engagement platform, reinsurance products, and broker/enrollment services.
Despite branding itself as a healthcare technology company, Oscar is classified under the Financials sector (GICS sub-industry: Life & Health Insurance), reflecting that its core revenue is generated through underwriting health insurance premiums rather than software sales. The company went public on March 3, 2021, and operates as a mid-cap stock with a market capitalization of approximately $9.1 billion USD.
- ACA marketplace enrollment growth boosts premium revenue
- Medical loss ratio improvement drives path to profitability
- +Oscar platform revenue scales with new payor partnerships
| Net Income: 550.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.39 > 0.02 and ΔFCF/TA 19.79 > 1.0 |
| NWC/Revenue: 4.46% < 20% (prev -5.15%; Δ 9.61% < -1%) |
| CFO/TA 0.39 > 3% & CFO 4.37b > Net Income 550.7m |
| Net Debt (-8.12b) to EBITDA (633.7m): -12.82 < 3 |
| Current Ratio: 1.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (333.4m) vs 12m ago 23.38% < -2% |
| Gross Margin: 34.60% > 18% (prev 31.64%; Δ 2.96% > 0.5%) |
| Asset Turnover: 174.0% > 50% (prev 168.0%; Δ 5.96% > 0%) |
| Interest Coverage Ratio: 33.55 > 6 (EBIT TTM 605.5m / Interest Expense TTM 18.0m) |
| A: 0.06 (Total Current Assets 9.37b - Total Current Liabilities 8.69b) / Total Assets 11.2b |
| B: -0.20 (Retained Earnings -2.25b / Total Assets 11.2b) |
| C: 0.07 (EBIT TTM 605.5m / Avg Total Assets 8.81b) |
| D: 0.22 (Book Value of Equity 2.05b / Total Liabilities 9.17b) |
| Altman-Z'' = 0.44 = B |
| DSRI: 0.36 (Receivables 380.1m/745.7m, Revenue 15.3b/10.7b) |
| GMI: 0.91 (GM 31.64% / 34.60%) |
| AQI: 0.50 (AQ_t 0.16 / AQ_t-1 0.31) |
| SGI: 1.43 (Revenue 15.3b / 10.7b) |
| TATA: -0.34 (NI 550.7m - CFO 4.37b) / TA 11.2b) |
| Beneish M = -3.66 (Cap -4..+1) = AAA |
As of October 04, 2026, the stock is trading at USD 30.94 with a total of 3,900,318 shares traded. Over the past week, the price has changed by +4.53%, over one month by +2.01%, over three months by -3.85% and over the past year by +60.48%.
Current recommended Stop Loss: 29.00 (which is 6.3% or 1.2 ATR below the current price).
Oscar Health has received a consensus analysts rating of 3.29. Therefore, it is recommended to hold OSCR.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 35.4 | 14.4% |
P/E Trailing = 22.7692
P/E Forward = 588.2353
P/S = 0.5964
P/B = 4.592
Revenue TTM = 15.3b USD
EBIT TTM = 605.5m USD
EBITDA TTM = 633.7m USD
Long Term Debt = 431.6m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 431.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -8.12b USD (calculated: Debt 431.6m - CCE 8.56b)
Enterprise Value = 1.01b USD (9.14b + Debt 431.6m - CCE 8.56b)
Interest Coverage Ratio = 33.55 (Ebit TTM 605.5m / Interest Expense TTM 18.0m)
EV/FCF = 0.23x (Enterprise Value 1.01b / FCF TTM 4.33b)
FCF Yield = 428.3% (FCF TTM 4.33b / Enterprise Value 1.01b)
FCF Margin = 28.30% (FCF TTM 4.33b / Revenue TTM 15.3b)
Net Margin = 3.60% (Net Income TTM 550.7m / Revenue TTM 15.3b)
Gross Margin = 34.60% ((Revenue TTM 15.3b - Cost of Revenue TTM 10.0b) / Revenue TTM)
Gross Margin QoQ = none% (prev 30.50%)
Tobins Q-Ratio = 0.09 (Enterprise Value 1.01b / Total Assets 11.2b)
Interest Expense / Debt = 4.18% (Interest Expense 18.0m / Debt 431.6m)
Taxrate = 6.59% (38.9m / 589.8m)
NOPAT = 565.5m (EBIT 605.5m * (1 - 6.59%))
Current Ratio = 1.08 (Total Current Assets 9.37b / Total Current Liabilities 8.69b)
Debt / Equity = 0.21 (Debt 431.6m / totalStockholderEquity, last quarter 2.05b)
Debt / EBITDA = -12.82 (Net Debt -8.12b / EBITDA 633.7m)
Debt / FCF = -1.87 (Net Debt -8.12b / FCF TTM 4.33b)
Total Stockholder Equity = 1.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.25% (Net Income 550.7m / Total Assets 11.2b)
RoE = 38.53% (Net Income TTM 550.7m / Total Stockholder Equity 1.43b)
RoCE = 32.53% (EBIT 605.5m / Capital Employed (Equity 1.43b + L.T.Debt 431.6m))
RoIC = 31.93% (NOPAT 565.5m / Invested Capital 1.77b)
WACC = 7.93% (E(9.14b)/V(9.57b) * Re(8.12%) + D(431.6m)/V(9.57b) * Rd(4.18%) * (1-Tc(0.07)))
Discount Rate = 8.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 41.80 | Cagr: 5.79%
[DCF] Terminal Value 77.97% ; FCFF base≈3.08b ; Y1≈3.53b ; Y5≈5.20b
[DCF] Fair Price = 315.8 (EV 78.2b - Net Debt -8.12b = Equity 86.4b / Shares 273.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.77 | # QB: 2
Revenue Correlation: 99.36 | Revenue CAGR: 43.65% | SUE: 0.75 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.17 | Chg30d=+31.83% | Revisions=-10% | Analysts=7
EPS current Year (2026-12-31): EPS=1.91 | Chg30d=+9.27% | Revisions=+73% | GrowthEPS=+213.2% | GrowthRev=+60.1%
EPS next Year (2027-12-31): EPS=2.17 | Chg30d=+15.07% | Revisions=+73% | GrowthEPS=+13.2% | GrowthRev=+11.0%
[Analyst] Revisions Ratio: +58% (up=19, down=4)